Helena Wållberg

On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a ¹²⁴I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model

Anna Orlova, Helena Wållberg, Sharon Stone‐Elander et al. · Journal of Nuclear Medicine · 2009 · 145 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Slow Internalization of Anti-HER2 Synthetic Affibody Monomer ¹¹¹ In-DOTA-Z _{HER2:342-pep2} : Implications for Development of Labeled Tracers

Helena Wållberg, Anna Orlova · Cancer Biotherapy and Radiopharmaceuticals · 2008 · 136 citations

Medicine, Biochemistry, Oncology +17

Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount

Vladimir Tolmachev, Daniel Rosik, Helena Wållberg et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2009 · 118 citations

Medicine, Oncology, Pharmacology +16

Targeting of HER2-Expressing Tumors with a Site-Specifically ^99mTc-Labeled Recombinant Affibody Molecule, Z_HER2:2395, with C-Terminally Engineered Cysteine

Sara Ahlgren, Helena Wållberg, Thuy Tran et al. · Journal of Nuclear Medicine · 2009 · 113 citations · Full text

Medicine, Biochemistry, Oncology +17

Targeting of <i>HER2</i>-Expressing Tumors Using ¹¹¹In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold

Sara Ahlgren, Anna Orlova, Helena Wållberg et al. · Journal of Nuclear Medicine · 2010 · 100 citations · Full text

Medicine, Medicinal Chemistry, Oncology +17